Shares closed at $127.75 on Monday, marking a second consecutive day of losses and trading 18.78% below the February 11th 52-week high.
Gilead's decline contrasted with Johnson & Johnson and Pfizer, which fell less, while Abbott Laboratories gained 1.83%. Trading volume reached 7.3 million, surpassing the 50-day average of 6.2 million.
The broader market was mixed, with the S&P 500 up 0.12% and the Dow Jones down 0.13%. Gilead's recent performance highlights ongoing volatility in the pharmaceutical sector.
Analysts see a bargain in Gilead's stock, so why did trading volume spike during its recent price drop?
Will pricing controversies over its new HIV drug undermine Gilead's long-term growth and reputation?
How will Gilead balance shareholder returns with demands for affordable access to its life-saving medicines?
With billions spent on acquisitions, can Gilead's new cancer drugs justify their price before key patents expire?
Can Gilead's newly acquired cancer therapies outmaneuver the increasingly fierce competition in the market?